Metabolic sequelae associated with androgen deprivation therapy for prostate cancer

Jason E Faris, Matthew R Smith, Jason E Faris, Matthew R Smith

Abstract

Purpose of review: To summarize the metabolic alterations associated with androgen deprivation therapy (ADT) for prostate cancer and to evaluate the evidence linking ADT with an increased risk of diabetes and cardiovascular disease.

Recent findings: ADT by either bilateral orchiectomy or treatment with gonadotropin-releasing hormone agonists causes changes in body composition, alterations in lipid profiles, and decreased insulin sensitivity. The spectrum of metabolic changes during ADT is distinct from classically described metabolic syndrome. Population-based, linked cancer registry studies have consistently reported significant associations between ADT and greater risk for diabetes mellitus. Some but not all studies have reported a link between ADT and cardiovascular disease risk. Most studies have reported no increase in cardiovascular mortality following ADT.

Summary: ADT appears causally associated with diabetes mellitus. ADT is also linked to cardiovascular morbidity, although there is less evidence that this relationship is causal.

Conflict of interest statement

The authors (Faris and Smith) declare no conflict of interest related to the contents of this manuscript.

Figures

Figure 1
Figure 1
Increased Incidence of Diabetes Mellitus and Myocardial Infarction with Androgen Deprivation Therapy [21]

References

    1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004 Jun 1;22(11):2141–9.
    1. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005 Apr 15;103(8):1615–24.
    1. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU international. 2006 Nov;98(5):973–8.
    1. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. The New England journal of medicine. 1984 Nov 15;311(20):1281–6.
    1. Garnick MB. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Urology. 1986 Jan;27(1 Suppl):21–8.
    1. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. British journal of urology. 1997 Feb;79(2):235–46.
    1. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. The New England journal of medicine. 1997 Jul 31;337(5):295–300.
    1. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol. 1997 Mar;15(3):1013–21.
    1. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. The New England journal of medicine. 1999 Dec 9;341(24):1781–8.
    1. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. Jama. 2004 Aug 18;292(7):821–7.
    1. Roach M, 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 1;26(4):585–91. Randomized clinical trial of radiation therapy with neoadjuvant ADT versus radiation therapy alone in 456 men with locally advanced prostate cancer. An increase in disease-free survival was observed with the use of ADT, and no difference in the risk of fatal cardiac events was observed.
    1. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. Journal of the National Cancer Institute. 2000 Apr 19;92(8):613–21.
    1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. Jama. 2005 Jul 13;294(2):238–44.
    1. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. The New England journal of medicine. 2005 Jan 13;352(2):154–64.
    1. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005 Nov 1;23(31):7897–903.
    1. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. The Journal of urology. 2006 Jan;175(1):136–9. discussion 9.
    1. Asbell SO, Leon SA, Tester WJ, Brereton HD, Ago CT, Rotman M. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. The Prostate. 1996 Oct;29(4):243–8.
    1. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. British journal of urology. 1997 Jun;79(6):933–41.
    1. Chander S, Choo R, Danjoux C, Morton G, Pearse A, Deboer G, et al. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. International journal of radiation oncology, biology, physics. 2005 Jul 1;62(3):719–24.
    1. Choo R, Chander S, Danjoux C, Morton G, Pearce A, Deboer G, et al. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? The Canadian journal of urology. 2005 Feb;12(1):2547–52.
    1. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 Sep 20;24(27):4448–56. This large retrospective SEER/Medicare study was the first to associate GnRH agonist therapy with an increased risk of diabetes and cardiovascular disease in men with prostate cancer.
    1. Baumgartner RN. Body composition in healthy aging. Annals of the New York Academy of Sciences. 2000 May;904:437–48.
    1. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Current opinion in clinical nutrition and metabolic care. 2008 Nov;11(6):693–700.
    1. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. Journal of endocrinological investigation. 1999;22(5 Suppl):110–6.
    1. Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. The European journal of medicine. 1992 Oct;1(6):329–36.
    1. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. The Journal of clinical endocrinology and metabolism. 1996 Dec;81(12):4358–65.
    1. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. The Journal of clinical endocrinology and metabolism. 1997 Feb;82(2):407–13.
    1. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. The Journal of clinical endocrinology and metabolism. 1999 Aug;84(8):2647–53.
    1. Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism: clinical and experimental. 1990 Dec;39(12):1314–9.
    1. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. The Journal of clinical endocrinology and metabolism. 2001 Sep;86(9):4261–7.
    1. Basaria S, Lieb J, 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clinical endocrinology. 2002 Jun;56(6):779–86.
    1. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. The Journal of urology. 2002 Jun;167(6):2361–7. discussion 7.
    1. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002 Nov 15;95(10):2136–44.
    1. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004 Apr;63(4):742–5.
    1. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005 Oct 15;104(8):1633–7.
    1. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. The Journal of clinical endocrinology and metabolism. 2002 Feb;87(2):599–603.
    1. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008 May 15;112(10):2188–94. Prospective study of GnRH administration to men with locally advanced or recurrent prostate cancer, demonstrating changes in body composition and lipid profiles that are distinct from metabolic syndrome.
    1. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. The Journal of clinical endocrinology and metabolism. 1998 Jun;83(6):1886–92.
    1. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003 Feb;104(2):195–201.
    1. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. The Journal of clinical endocrinology and metabolism. 2006 Apr;91(4):1305–8.
    1. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. The Journal of urology. 2009 May;181(5):1998–2006. discussion 7–8.
    1. Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. The Journal of urology. 1995 Jul;154(1):100–4.
    1. Eri LM, Urdal P. Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. European urology. 1995;27(4):274–9.
    1. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) Jama. 1986 Nov 28;256(20):2823–8.
    1. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007 Dec 1;370(9602):1829–39.
    1. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007 Jan 30;115(4):450–8.
    1. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. Jama. 2008 Nov 12;300(18):2142–52.
    1. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. Jama. 2009 Nov 11;302(18):1993–2000. Analysis of 68 long-term prospective studies examining association between lipid profiles and vascular outcomes.
    1. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. The New England journal of medicine. 1996 Apr 11;334(15):952–7.
    1. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998 Aug 4;98(5):398–404.
    1. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke; a journal of cerebral circulation. 1998 Sep;29(9):1860–6.
    1. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes care. 2005 Jul;28(7):1636–42.
    1. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. Journal of andrology. 2009 Jan-Feb;30(1):23–32.
    1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) Jama. 2001 May 16;285(19):2486–97.
    1. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. The Journal of clinical endocrinology and metabolism. 2006 Mar;91(3):843–50.
    1. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. The Journal of clinical endocrinology and metabolism. 2005 May;90(5):2618–23.
    1. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006 Aug 20;24(24):3979–83.
    1. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007 Jul 3;116(1):39–48.
    1. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. The American journal of cardiology. 2006 Jan 16;97(2A):3A–11A.
    1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama. 2002 Dec 4;288(21):2709–16.
    1. Reaven GM. The metabolic syndrome: requiescat in pace. Clinical chemistry. 2005 Jun;51(6):931–8.
    1. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2005 Sep;28(9):2289–304.
    1. Iribarren C, Go AS, Husson G, Sidney S, Fair JM, Quertermous T, et al. Metabolic syndrome and early-onset coronary artery disease: is the whole greater than its parts? Journal of the American College of Cardiology. 2006 Nov 7;48(9):1800–7.
    1. Hakimian P, Blute M, Jr, Kashanian J, Chan S, Silver D, Shabsigh R. Metabolic and cardiovascular effects of androgen deprivation therapy. BJU international. 2008 Dec;102(11):1509–14.
    1. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes care. 2000 Apr;23(4):490–4.
    1. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European journal of endocrinology/European Federation of Endocrine Societies. 2006 Jun;154(6):899–906.
    1. Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology. 2007 Dec;70(6):1104–8.
    1. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009 Jul 20;27(21):3452–8. This retrospective matched cohort study performed in Ontario reported an association of androgen deprivation therapy with diabetes, but no increase in cardiovascular mortality.
    1. Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. Journal of the National Cancer Institute. Jan 6;102(1):39–46. Retrospective Veterans Administration database study, with a younger patient population associating ADT with increased risk of diabetes and cardiovascular morbidity.
    1. Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998 Sep 15;83(6):1180–8.
    1. Lu-Yao GST, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171:2285–90.
    1. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. European heart journal. 2000 Jun;21(11):890–4.
    1. Yaron M, Greenman Y, Rosenfeld JB, Izkhakov E, Limor R, Osher E, et al. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. European journal of endocrinology/European Federation of Endocrine Societies. 2009 May;160(5):839–46.
    1. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. The Journal of clinical endocrinology and metabolism. 2008 Jan;93(1):68–75.
    1. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellstrom D, et al. Low serum testosterone and estradiol predict mortality in elderly men. The Journal of clinical endocrinology and metabolism. 2009 Jul;94(7):2482–8.
    1. Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation. 2005 Jul 19;112(3):332–40.
    1. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. Archives of internal medicine. 2007 Jun 25;167(12):1252–60.
    1. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007 Oct 1;110(7):1493–500.
    1. Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute. 2007 Oct 17;99(20):1516–24.
    1. D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007 Jun 10;25(17):2420–5.
    1. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006 Apr 20;24(12):1868–76.
    1. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92–02. European urology. 2008 Oct;54(4):816–23.
    1. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009 Jan 1;27(1):92–9. Randomized clinical trial involving 945 men with locally advanced prostate cancer randomized to radiation therapy with GnRH agonist therapy versus radiation alone demonstrating no increase in cardiovascular mortality.
    1. Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. Journal of general internal medicine. 2009 Nov;24(Suppl 2):S389–94. Randomized clinical trial involving 945 men with locally advanced prostate cancer randomized to radiation therapy with GnRH agonist therapy versus radiation alone demonstrating no increase in cardiovascular mortality.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit